Published on

Clinical Toxicology — Propylthiouracil

1. Overview

Propylthiouracil (PTU) is a thionamide antithyroid medication used to suppress thyroid hormone synthesis in patients with hyperthyroidism.

Unlike most medications discussed in acute overdose toxicology, PTU rarely causes severe toxicity after an isolated ingestion. Its most important hazards arise during therapeutic administration and include fulminant hepatotoxicity, agranulocytosis, ANCA-associated vasculitis, and excessive suppression of thyroid function.

Severe liver injury can occur unpredictably and has led to liver transplantation and death, including in children. PTU therefore carries an FDA boxed warning and is no longer the preferred antithyroid medication for most patients.

The essential clinical distinction is between:

  • Acute overdose: Usually mild, requiring supportive care and exposure assessment.
  • Idiosyncratic adverse reactions: Potentially life-threatening even at ordinary prescribed doses.
  • Excessive thyroid suppression: May cause hypothyroidism and, during pregnancy, fetal thyroid dysfunction.

There is no specific antidote to PTU poisoning.

2. Forms, indications, and therapeutic use

PTU is generally supplied as 50 mg oral tablets.

Its principal uses are treatment of Graves’ hyperthyroidism or toxic multinodular goiter in selected patients who cannot tolerate methimazole, and temporary management of hyperthyroidism before definitive therapy when methimazole is unsuitable.

PTU also has an important role in thyroid storm because it inhibits peripheral conversion of thyroxine (T4) to triiodothyronine (T3).

Contemporary treatment selection

Methimazole is usually preferred for routine antithyroid treatment because of its dosing convenience and lower risk of severe hepatocellular injury.

PTU remains an important option when:

  • Antithyroid treatment is needed in early pregnancy.
  • Thyroid storm requires urgent control.
  • Methimazole cannot be tolerated and other treatment options are inappropriate.

PTU is generally not recommended for children, except in rare circumstances where methimazole is unsuitable and definitive alternatives are inappropriate.

Therapeutic dosing

Adult labeling commonly describes an initial dose of 300 mg/day in three divided doses, sometimes increased to 400 mg/day or, in selected severe disease, 600–900 mg/day.

Maintenance dosing is generally 100–150 mg/day, adjusted according to thyroid function and clinical response.

These are therapeutic prescribing ranges, not toxic-dose thresholds.

3. Mechanism of action

PTU inhibits thyroid peroxidase-mediated reactions, including iodination of tyrosine residues within thyroglobulin and the coupling reactions required for thyroid hormone synthesis.

It also inhibits peripheral conversion of T4 to the more biologically active T3.

Why its effects are delayed

PTU does not directly block the release of thyroid hormone already stored within the thyroid gland.

Consequently, thyroid hormone concentrations decline gradually during ordinary treatment.

Clinical improvement is often evident over days to weeks, while normalization may require several weeks.

Clinical implication

A single overdose does not usually cause immediate profound hypothyroidism because circulating and stored thyroid hormone remain available.

Repeated excessive treatment, however, can suppress thyroid hormone production sufficiently to cause clinically important hypothyroidism.

4. Toxicokinetics and toxic dose

PTU is absorbed after oral administration and extensively metabolized, with metabolites and some unchanged drug eliminated through the kidneys.

Its plasma elimination half-life is relatively short, generally around one to two hours, but its antithyroid effects persist longer.

Acute overdose

A minimum toxic or lethal dose has not been established.

Historical reports describe ingestion of several grams without serious immediate effects.

However, the clinical course cannot be predicted reliably from dose alone.

Reported overdose manifestations include nausea, vomiting, abdominal discomfort, headache, rash, fever, and arthralgia. Rare serious hematologic or hepatic effects are recognized, although these complications are more strongly associated with ongoing treatment than with a single ingestion.

Clinical distinction

A large one-time dose is not necessarily more dangerous than an ordinary therapeutic dose that triggers a severe idiosyncratic reaction.

The exposure history must therefore establish both the amount ingested and the duration of prior PTU treatment.

5. Major adverse effects

Adverse effect

Key warning features

Clinical importance

Severe hepatotoxicity

Fatigue, anorexia, abdominal pain, dark urine, jaundice

Acute liver failure, transplantation, death

Agranulocytosis

Fever, sore throat, oral ulcers, infection

Potentially fatal neutropenic sepsis

ANCA-associated vasculitis

Rash, hematuria, breathlessness, hemoptysis

Glomerulonephritis or pulmonary hemorrhage

Hypothyroidism

Fatigue, cold intolerance, constipation, bradycardia

Excessive thyroid suppression

Mild hypersensitivity

Rash, itching, arthralgia

May require treatment change

Other rare hematologic injury

Bruising, bleeding, pallor, recurrent infections

Thrombocytopenia or pancytopenia

Severe liver injury

PTU can produce predominantly hepatocellular injury, sometimes progressing rapidly to acute liver failure.

Cases have occurred during the first several months of treatment, although later presentations are possible.

Warning symptoms include profound fatigue, loss of appetite, nausea, pruritus, right-upper-quadrant discomfort, dark urine, pale stools, and jaundice.

Suspected PTU-associated hepatitis requires immediate discontinuation and urgent clinical evaluation.

Evaluation should include AST, ALT, bilirubin, and INR, with additional investigations guided by the severity of illness.

Patients with jaundice, coagulopathy, encephalopathy, or rapidly worsening laboratory results require hospital assessment and early hepatology involvement.

Agranulocytosis

Agranulocytosis occurs in approximately 0.2–0.5% of patients treated with PTU or related antithyroid medications.

It often develops within the first three months of treatment but may occur later or after restarting therapy.

Patients may present abruptly with fever, severe sore throat, mouth ulcers, or other signs of infection.

A complete blood count with differential is required urgently.

When agranulocytosis is suspected, PTU should be stopped pending immediate medical assessment.

Confirmed cases require appropriate infection management, frequently hospitalization, and sometimes granulocyte colony-stimulating factor after specialist consultation.

ANCA-associated vasculitis

PTU can trigger immune-mediated small-vessel vasculitis, often associated with myeloperoxidase-ANCA (MPO-ANCA).

Clinical manifestations may include palpable purpura, joint pain, kidney inflammation, and pulmonary hemorrhage.

Blood in the urine, reduced kidney function, unexplained breathlessness, or coughing blood are major warning findings.

Management involves discontinuing PTU and assessing organ involvement. Severe pulmonary or renal disease may require specialist immunosuppressive treatment.

ANCA positivity alone does not establish clinical vasculitis; testing must be interpreted alongside symptoms, examination, and organ findings.

Hypothyroidism

Excessive or prolonged suppression of thyroid hormone synthesis can cause hypothyroidism.

Symptoms may include fatigue, cold intolerance, constipation, weight gain, and bradycardia.

Severe hypothyroidism is uncommon when thyroid function is monitored appropriately.

During pregnancy, excessive PTU exposure can also cause fetal hypothyroidism or goiter.

6. Diagnosis and investigations

Exposure history

Determine the dose, time of ingestion, duration of previous treatment, underlying thyroid disorder, other medications, and whether the patient is pregnant.

Ask specifically about fever, sore throat, jaundice, dark urine, rash, joint pain, hematuria, and respiratory symptoms.

Minor isolated ingestion

An asymptomatic patient after a reliably minor accidental exposure may require no laboratory testing, depending on poison-center assessment.

Significant ingestion or symptoms

Possible investigations include:

  • CBC with differential: Neutropenia, agranulocytosis, or other cytopenias.
  • AST, ALT, bilirubin, and INR: Hepatic injury and synthetic function.
  • Electrolytes, glucose, and creatinine: Metabolic or renal complications.
  • TSH and free T4: Thyroid status when relevant.
  • Free or total T3: Particularly useful in severe thyrotoxicosis or thyroid storm.
  • Urinalysis: Hematuria or proteinuria suggesting vasculitis.
  • ECG: Significant cardiovascular symptoms or suspected coingestion.

ANCA testing, inflammatory markers, chest imaging, and specialist renal investigations may be appropriate when vasculitis is suspected.

PTU concentrations

Serum PTU measurements are not routinely available and have no established role in emergency overdose management.

Thyroid testing limitation

TSH may remain suppressed for months after treatment of hyperthyroidism begins, so free T4 and T3 are more informative during early treatment adjustment.

7. Treatment of acute overdose

Initial management

Acute PTU overdose is generally managed with supportive care.

Assess airway, breathing, circulation, vital signs, mental status, and potential coingestants.

Most isolated ingestions do not require intensive resuscitation.

Gastrointestinal decontamination

Do not induce vomiting.

Routine gastric lavage is not recommended.

Activated charcoal may be considered after a substantial recent ingestion when the airway is protected, but its clinical benefit for isolated PTU overdose is uncertain.

Charcoal should not be given automatically to every patient.

Symptomatic treatment

Treat vomiting, dehydration, and other symptoms as clinically indicated.

Important electrolyte disturbances or cardiovascular abnormalities require conventional treatment.

If a serious adverse reaction is identified, PTU should be stopped and the complication managed specifically.

Antidote

There is no specific antidote for PTU.

Hemodialysis and hemoperfusion are not established treatments for enhancing PTU elimination.

8. Management of severe treatment-related complications

Acute liver injury

Discontinue PTU immediately.

Monitor hepatic enzymes, bilirubin, INR, glucose, renal function, and mental status.

Avoid unnecessary hepatotoxic medications.

Acute liver failure requires urgent hepatology and liver-transplant-center assessment when appropriate.

Agranulocytosis

Stop PTU immediately.

Patients with fever and severe neutropenia require urgent infection evaluation and empiric antimicrobial therapy according to contemporary febrile neutropenia protocols.

Hematology consultation is appropriate in serious cases.

Vasculitis

Stop PTU and assess renal, pulmonary, and other organ involvement.

Kidney function, urinalysis, urine protein assessment, and chest imaging may be necessary.

Severe organ-threatening vasculitis requires specialist treatment, potentially including glucocorticoids and additional immunosuppressive agents.

Plasma exchange is not a routine treatment for every patient with ANCA-associated vasculitis.

Excessive thyroid suppression

Reduce or withhold further antithyroid treatment as directed by the treating clinician, and monitor thyroid hormone concentrations.

The underlying hyperthyroidism may recur after stopping PTU, so an alternative treatment plan is essential.

9. PTU in thyroid storm

The historical statement that iodine must follow every initial PTU dose is incorrect for routine hyperthyroidism treatment.

Iodine administration is part of selected thyroid storm protocols, not an automatic accompaniment to ordinary PTU therapy.

Thyroid storm is a life-threatening state of severe thyrotoxicosis requiring intensive treatment.

A commonly used regimen includes an initial high PTU dose of 500–1,000 mg, followed by approximately 250 mg every four hours, with subsequent adjustment according to clinical response.

Additional treatment may include:

  • Carefully selected beta blockade, with particular caution in decompensated heart failure.
  • Glucocorticoids.
  • Supportive temperature and circulatory management.
  • Iodine administered after the thionamide, commonly at least one hour later.

Administering iodine only after a thionamide reduces the risk that iodine could be used for additional thyroid hormone synthesis.

Methimazole is an alternative when PTU is unsuitable.

These high doses and combination treatments apply to thyroid storm under specialist supervision, not routine outpatient treatment or PTU overdose.

10. Monitoring during therapeutic treatment

Baseline CBC with differential and liver tests are useful before starting antithyroid treatment.

Thyroid function should then be assessed periodically, with free T4 and T3 commonly measured approximately 2–6 weeks after initiation, followed by adjustments based on response.

CBC monitoring

Routine scheduled CBC testing has not been proven to prevent agranulocytosis, which may develop abruptly.

However, fever or sore throat requires an urgent differential white blood cell count.

Liver monitoring

Routine scheduled liver tests have not reliably prevented severe PTU hepatotoxicity because injury may develop rapidly and unpredictably.

Any clinical symptoms suggesting liver dysfunction require prompt liver testing and immediate treatment reassessment.

Thyroid function

The dose should be adjusted to maintain an appropriate thyroid state without overtreatment.

When PTU is discontinued, continued follow-up is needed to detect recurrent hyperthyroidism.

Treatment changes

A patient who develops serious agranulocytosis should generally not be switched casually to another thionamide because serious cross-reactions are possible.

Definitive treatment with radioactive iodine or thyroidectomy may be necessary, depending on the clinical situation.

11. Pregnancy and breastfeeding

Pregnancy

The old FDA Pregnancy Category D system is obsolete.

Both methimazole and PTU cross the placenta.

When antithyroid treatment is needed in early pregnancy, PTU is often preferred because the characteristic birth defects associated with methimazole exposure are generally more concerning during organ formation.

American Thyroid Association guidance favors PTU through approximately week 16 of pregnancy when antithyroid therapy is necessary.

After the first trimester, switching to methimazole may be considered to limit maternal hepatotoxicity risk.

However, the decision is individualized: switching can temporarily destabilize thyroid control, and the ATA recognizes that continuing PTU may be appropriate in selected patients.

Use the lowest effective antithyroid dose, with appropriate maternal and fetal monitoring.

Breastfeeding

PTU enters breast milk in small quantities.

However, the earlier assumption that PTU is necessarily preferred during breastfeeding is no longer accepted.

Because of the mother’s risk of serious PTU-associated liver injury, methimazole is generally preferred during lactation when otherwise suitable.

PTU remains compatible with breastfeeding in selected circumstances, commonly at doses not exceeding 450 mg/day, under appropriate medical supervision.

Routine thyroid laboratory testing of every breastfed infant is not recommended solely because the mother takes a standard antithyroid medication dose. Normal growth and development should be assessed through usual pediatric follow-up, with additional testing when clinically indicated.

12. Drug interactions

PTU-related interactions arise both from direct drug effects and from changes in metabolism as hyperthyroidism is corrected.

Warfarin: PTU may increase anticoagulant effects through effects on vitamin K activity. INR monitoring is appropriate when therapy changes.

Beta blockers: Drug requirements may decrease as the patient becomes euthyroid because clearance and physiologic sensitivity can change.

Digoxin: Serum concentrations and treatment requirements can change with correction of hyperthyroidism.

Theophylline: Clearance may decrease as hyperthyroidism resolves, potentially increasing the risk of adverse effects.

Other marrow-suppressing medications: Concurrent treatment may complicate the risk or recognition of neutropenia.

A medication review is important whenever PTU is initiated, stopped, or substantially adjusted.

13. Observation, disposition, and prognosis

Isolated acute ingestion

Many asymptomatic patients with a reliably isolated acute ingestion can be managed after poison-center assessment without hospitalization.

There is no validated toxic-dose threshold or universal observation interval.

The decision depends on the estimated amount, symptoms, age, comorbidities, chronic PTU exposure, and potential coingestants.

Hospital admission

Admission is appropriate for significant hepatic injury, severe neutropenia or infection, organ-threatening vasculitis, serious metabolic abnormalities, or clinically important symptoms requiring treatment.

Intensive care

ICU treatment may be required for acute liver failure, septic shock associated with agranulocytosis, pulmonary hemorrhage, or other critical organ dysfunction.

Expected course

The prognosis after a minor isolated PTU ingestion is generally favorable.

Mild allergic or gastrointestinal adverse effects usually improve after the drug is stopped.

However, idiosyncratic liver injury and agranulocytosis can be fatal despite appropriate prescribed dosing.

Vasculitis may resolve after PTU discontinuation, but serious kidney or pulmonary injury may require prolonged treatment.

14. Clinical pitfalls

Historical assumption

Contemporary correction

PTU is a routine first-line antithyroid agent

Methimazole is generally preferred

PTU is appropriate for routine pediatric treatment

PTU is generally avoided in children because of severe liver-injury risk

Toxicity is mainly caused by large doses

Life-threatening idiosyncratic reactions can occur at therapeutic doses

A normal early CBC excludes agranulocytosis

Agranulocytosis may develop abruptly

Regular liver tests reliably prevent hepatic failure

Routine testing has not been shown to prevent unpredictable severe injury

All PTU-treated patients need iodine after dosing

Iodine following a thionamide is relevant to selected thyroid storm protocols

PTU is always preferred during breastfeeding

Methimazole is now generally preferred when suitable

An ANCA-positive result always indicates vasculitis

Clinical and organ findings determine whether vasculitis is present

Thyroid hormone suppression is immediate

Previously synthesized and circulating hormone remains available

TSH alone is sufficient for early treatment monitoring

Free T4 and T3 are more useful initially

Routine gastric lavage is indicated after a large ingestion

Gastric lavage is not recommended routinely

Serious symptoms require only supportive care

Hepatic failure, agranulocytosis, and vasculitis require specific urgent management


Key clinical conclusions

PTU is an important but potentially hazardous antithyroid medication whose principal risks occur during treatment rather than after isolated acute overdose.

The most serious complications are acute liver failure, agranulocytosis, and ANCA-associated vasculitis.

PTU should be reserved for appropriate indications, with strong emphasis on patient education and rapid evaluation of warning symptoms.

Fever or sore throat calls for urgent assessment of the neutrophil count. Jaundice, dark urine, or significant abdominal pain requires immediate investigation for liver injury. Hematuria, reduced kidney function, or coughing blood raises concern for vasculitis.

Acute overdose is generally managed supportively. There is no specific antidote.


Image description
0 Comments